Crescent Biopharma, Inc.

Crescent Biopharma, Inc.

CBIO·NASDAQ

$18.45

+8.5%
HealthcareBiotechnology

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$508.70M
EPS-14.7800
P/E Ratio-1.25
Earnings Date07/30/2026

cbio

Inventory

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Crescent Biopharma, Inc.

Crescent Biopharma, Inc. Competitors Analysis of Inventory

CBIO · NASDAQ
CompanyInventory
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
92.75M
30.1%13.9%33.0%
Crescent Biopharma, Inc.

Crescent Biopharma, Inc. Fair Value Envelope

CBIO · NASDAQ

Our analysis suggests that CBIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $18.45, this represents a potential HIDDEN relative to our calculated worth for Crescent Biopharma, Inc..

Intrinsic Value
Current Price: $18.45